Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16541488 | 1.00 | DPP4 (0.37) | DPP4MCL1ALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL17351504 | 0.98 | MCL1 (0.37) | DPP4MCL1ALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL18692589 | 0.94 | MCL1 (0.37) | DPP4MCL1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL283516 | 0.89 | — | — | |
| SCHEMBL12282538 | 0.80 | RIPK1 (0.35) | DPP4MCL1CTSK | |
| SCHEMBL16784430 | 0.78 | — | — | |
| SCHEMBL9713149 | 0.76 | CETP (0.36) | DPP4MCL1ALDH1A1HSD17B10CTSL | |
| SCHEMBL12614640 | 0.76 | MEN1 (0.31) | MCL1ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL16866560 | 0.75 | MCL1 (0.35) | MCL1ALDH1A1KMT2A | |
| SCHEMBL1255072 | 0.75 | MCL1 (0.35) | MCL1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| WO-2011121366-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| US-20070185057-A1 | Novel Indanone Compounds | SYMRISE GMBH & CO. KG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-7208142-B2 | Indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2007-04-24 | — | — | US | disclosed |
| CN-1246303-C | Indanylidene compounds | THIMRASS KG (DE) | 2006-03-22 | — | — | CN | disclosed |
| EP-1466892-A1 | Novel indanylidene compounds | Symrise GmbH & Co. KG (DE) | 2004-10-13 | — | — | EP | disclosed |
| EP-1341752-B1 | NOVEL INDANYLIDENE COMPOUNDS | SYMRISE GMBH & CO KG (DE) | 2004-08-04 | — | — | EP | disclosed |
| CN-1473146-A | Novel indanylidene compounds | ��������ķ������ | 2004-02-04 | — | — | CN | disclosed |
| US-20020143203-A1 | Novel indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2002-10-03 | — | — | US | disclosed |
| EP-0135252-A2 | Process for preparing 3-substituted-3-aminonitrile | ELI LILLY AND COMPANY (US) | 1985-03-27 | — | — | EP | disclosed |
| EP-0129408-A2 | (3-alkyl-5-isothiazolyl)ureas | ELI LILLY AND COMPANY (US) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185057-A1 | Novel Indanone Compounds | CUTA, NISCH, TYR | DPP4 4266/4885MCL1 4016/4885ALDH1A1 434/4885 |
| US-20170362208-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | DPP4 2480/4885MCL1 1077/4885ALDH1A1 755/4885 |
| US-20020143203-A1 | Novel indanylidene compounds | CUTA, NISCH, ERCC4 | DPP4 4101/4885MCL1 3360/4885ALDH1A1 373/4885 |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | MAPK1, MAP3K1, MAPK3 | DPP4 3402/4885MCL1 655/4885ALDH1A1 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.